Brief: Citius Pharmaceuticals Says Receives Response Letter From US FDA For Lymphir For The Treatment Of Patients With Relapsed Or Refractory Cutaneous T-Cell Lymphoma
29/07/2023 21:18
July 29 (Reuters) - Citius Pharmaceuticals Inc CTXR.O :
* CITIUS PHARMACEUTICALS, INC. RECEIVES A COMPLETE RESPONSE
LETTER
FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR LYMPHIR™
(DENILEUKIN DIFTITOX) FOR THE TREATMENT OF PATIENTS WITH
RELAPSED OR REFRACTORY CUTANEOUS T-CELL LYMPHOMA
* CITIUS PHARMACEUTICALS INC SAYS NO CLINICAL EFFICACY OR
SAFETY
ISSUES RAISED
Source text for Eikon: ID:nPn7TbGtTa
Further company coverage: CTXR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Citius Pharmaceuticals
See all newsCitius Pharmaceuticals Q2 revenue rises on LYMPHIR launch
Citius Pharmaceuticals reports first revenue of $3.9 mln
Brief: Citius Oncology Expands International Distribution Of Lymphir™ To European Union Through Exclusive Agreement With Uniphar
Brief: Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results And Provides Business Update
Brief: Citius Oncology Announces $18 Million Concurrent Registered Direct Offering And Private Placement Priced At-The-Market Under Nasdaq Rules